Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

References

• AllemaniCWeirHKCarreiraHGlobal surveillance of cancer survival 1995–2009 analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)Lancet Epub11262014
   Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• LittleAGGayEGGasparLEStewartAKNational survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of careLung Cancer200757325326017451842
   PubMed Web of Science ®Google Scholar
• GiacconeGEpidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancerJ Clin Oncol200523143235324215886311
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• ThomasRKBakerACDebiasiRMHigh-throughput oncogene mutation profiling in human cancerNat Genet200739334735117293865
   PubMed Web of Science ®Google Scholar
• SuZDias-SantagataDDukeMA platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancerJ Mol Diagn2011131748421227397
   PubMed Web of Science ®Google Scholar
• LiTKungHJMackPCGandaraDRGenotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapiesJ Clin Oncol20133181039104923401433
   PubMed Web of Science ®Google Scholar
• DingLGetzGWheelerDASomatic mutations affect key pathways in lung adenocarcinomaNature200845572161069107518948947
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinomaNature2014511751154355025079552
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• AzzoliCGTeminSAliffTAmerican Society of Clinical Oncology2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung CancerJ Clin Oncol201129283825383121900105
   PubMed Web of Science ®Google Scholar
• PistersKMEvansWKAzzoliCGCancer Care Ontario; American Society of Clinical OncologyCancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guidelineJ Clin Oncol200725345506551817954710
   PubMed Web of Science ®Google Scholar
• CurranWJJrPaulusRLangerCJSequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410J Natl Cancer Inst2011103191452146021903745
   PubMedGoogle Scholar
• SuSFHuYXOuyangWWOverall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center studyBMC Cancer20131347424118842
   PubMed Web of Science ®Google Scholar
• OwonikokoTKArbiserJZelnakACurrent approaches to the treatment of metastatic brain tumoursNat Rev Clin Oncol201411420322224569448
   PubMed Web of Science ®Google Scholar
• RossiARicciardiSMaionePde MarinisFGridelliCPemetrexed in the treatment of advanced non-squamous lung cancerLung Cancer200966214114919577816
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• LangerCJBesseBGualbertoABrambillaESoriaJCThe evolving role of histology in the management of advanced non-small-cell lung cancerJ Clin Oncol201028365311532021079145
   PubMed Web of Science ®Google Scholar
• NohSShimHOptimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areasLung Cancer2012761515521978426
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med2008358111160117418337605
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• ChongCRJännePAThe quest to overcome resistance to EGFR-targeted therapies in cancerNat Med201319111389140024202392
   PubMed Web of Science ®Google Scholar
• CampoliMFerrisRFerroneSWangXImmunotherapy of malignant disease with tumor antigen-specific monoclonal antibodiesClin Cancer Res2010161112020028761
   PubMed Web of Science ®Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaAFLEX Study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• LeeJKShinJYKimSPrimary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory studyAnn Oncol20132482080208723559152
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A200810562070207518227510
   PubMed Web of Science ®Google Scholar
• DienstmannRDe DossoSFelipETaberneroJDrug development to overcome resistance to EGFR inhibitors in lung and colorectal cancerMol Oncol201261152622189054
   PubMed Web of Science ®Google Scholar
• CrossDAAshtonSEGhiorghiuSAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerCancer Discov2014491046106124893891
   PubMed Web of Science ®Google Scholar
• OhashiKSequistLVArcilaMELung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Proc Natl Acad Sci U S A201210931E2127E213322773810
   PubMed Web of Science ®Google Scholar
• GarofaloMRomanoGDi LevaGEGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersNat Med2012181748222157681
   PubMed Web of Science ®Google Scholar
• UramotoHIwataTOnitsukaTShimokawaHHanagiriTOyamaTEpithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinomaAnticancer Res20103072513251720682976
   PubMed Web of Science ®Google Scholar
• AlamNGustafsonKSLadanyiMSmall-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lungClin Lung Cancer2010115E1E420837450
   PubMed Web of Science ®Google Scholar
• LipsonDCapellettiMYelenskyRIdentification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNat Med201218338238422327622
   PubMed Web of Science ®Google Scholar
• PulfordKLamantLEspinosEThe emerging normal and disease-related roles of anaplastic lymphoma kinaseCell Mol Life Sci200461232939295315583856
   PubMed Web of Science ®Google Scholar
• RenHTanZPZhuXIdentification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancerCancer Res201272133312332322570254
   PubMed Web of Science ®Google Scholar
• GridelliCPetersSSgambatoACasaluceFAdjeiAACiardielloFALK inhibitors in the treatment of advanced NSCLCCancer Treat Rev201440230030623931927
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• CasaluceFSgambatoAMaionePALK inhibitors: a new targeted therapy in the treatment of advanced NSCLCTarget Oncol201381556723325296
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Natl Acad Sci U S A200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• BowlesDWWeickhardtAJDoebeleRCCamidgeDRJimenoACrizotinib for the treatment of patients with advanced non-small cell lung cancerDrugs Today (Barc)201248427128222536569
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• KodamaTTsukaguchiTYoshidaMKondohOSakamotoHSelective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceCancer Lett2014351221522124887559
   PubMed Web of Science ®Google Scholar
• TsutaKKohnoTYoshidaARET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysisBr J Cancer201411061571157824504365
   PubMed Web of Science ®Google Scholar
• DrilonAWangLHasanovicAResponse to Cabozantinib in patients with RET fusion-positive lung adenocarcinomasCancer Discov20133663063523533264
   PubMed Web of Science ®Google Scholar
• GautschiOZanderTKellerFAA patient with lung adenocarcinoma and RET fusion treated with vandetanibJ Thorac Oncol201385e43e4423584301
   PubMed Web of Science ®Google Scholar
• WangRHuHPanYRET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancerJ Clin Oncol201230354352435923150706
   PubMed Web of Science ®Google Scholar
• TurnerNGroseRFibroblast growth factor signalling: from development to cancerNat Rev Cancer201010211612920094046
   PubMed Web of Science ®Google Scholar
• WeissJSosMLSeidelDFrequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerSci Transl Med201026262r a93.
   Web of Science ®Google Scholar
• BremnesRMCampsCSireraRAngiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and bloodLung Cancer200651214315816360975
   PubMed Web of Science ®Google Scholar
• IwasakiAKuwaharaMYoshinagaYShirakusaTBasic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLCEur J Cardiothorac Surg200425344344815019676
   PubMed Web of Science ®Google Scholar
• KuhnHKöpffCKonradJRiedelAGessnerCWirtzHInfluence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell linesLung Cancer200444216717415084381
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• GozgitJMWongMJMoranLPonatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsMol Cancer Ther201211369069922238366
   PubMed Web of Science ®Google Scholar
• GavinePRMooneyLKilgourEAZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyCancer Res20127282045205622369928
   PubMed Web of Science ®Google Scholar
• DoebeleRCConklingPTraynorAMA phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerAnn Oncol20122382094210222345119
   PubMed Web of Science ®Google Scholar
• RenMHongMLiuGNovel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1Oncol Rep20132962181219023563700
   PubMed Web of Science ®Google Scholar
• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov20098862764419644473
   PubMed Web of Science ®Google Scholar
• ZitoCRJilaveanuLBAnagnostouVMulti-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cellsPLoS One201272e3133122355357
   PubMed Web of Science ®Google Scholar
• XuCFillmoreCMKoyamaSLoss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionCancer Cell201425559060424794706
   PubMed Web of Science ®Google Scholar
• YamamotoHShigematsuHNomuraMPIK3CA mutations and copy number gains in human lung cancersCancer Res200868176913692118757405
   PubMed Web of Science ®Google Scholar
• BeckJTIsmailATolomeoCTargeting the phosphatidylinositol 3- kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinomaCancer Treat Rev201440898098925037117
   PubMed Web of Science ®Google Scholar
• MairaSMPecchiSHuangAIdentification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorMol Cancer Ther201211231732822188813
   PubMed Web of Science ®Google Scholar
• BendellJCRodonJBurrisHAPhase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJ Clin Oncol201230328229022162589
   PubMed Web of Science ®Google Scholar
• IhleNTWilliamsRChowSMolecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingMol Cancer Ther20043776377215252137
   PubMed Web of Science ®Google Scholar
• KeysarSBAstlingDPAndersonRTA patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsMol Oncol20137477679023607916
   PubMed Web of Science ®Google Scholar
• HongDSBowlesDWFalchookGSA multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumorsClin Cancer Res201218154173418222693357
   PubMed Web of Science ®Google Scholar
• FritschCHuangAChatenay-RivaudayCCharacterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trialsMol Cancer Ther20141351117112924608574
   PubMed Web of Science ®Google Scholar
• FuretPGuagnanoVFairhurstRADiscovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluationBioorg Med Chem Lett201323133741374823726034
   PubMed Web of Science ®Google Scholar
• BiankinAVWaddellNKassahnKSAustralian Pancreatic Cancer Genome InitiativePancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature2012491742439940523103869
   PubMed Web of Science ®Google Scholar
• Khosravi-FarRDerCJThe Ras signal transduction pathwayCancer Metastasis Rev199413167898143346
   PubMed Web of Science ®Google Scholar
• ShepherdFADomergCHainautPPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapyJ Clin Oncol201331172173218123630215
   PubMed Web of Science ®Google Scholar
• LuYBellgrauDDwyer-NieldLDMutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapyCancer Res200464155084508815289309
   PubMed Web of Science ®Google Scholar
• ChaftJELitvakAArcilaMEPhase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I–III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutationClin Lung Cancer201415640541025044103
   PubMed Web of Science ®Google Scholar
• EngelmanJAChenLTanXEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNat Med200814121351135619029981
   PubMed Web of Science ®Google Scholar
• EbiHFaberACEngelmanJAYanoSNot just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancersCancer Sci2014105549950524612015
   PubMed Web of Science ®Google Scholar
• CorcoranRBChengKAHataANSynthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsCancer Cell201323112112823245996
   PubMed Web of Science ®Google Scholar
• ChenRSweet-CorderoEATwo is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancerCancer Discov20133549149323658296
   PubMed Web of Science ®Google Scholar
• ZhuZArefARCohoonTJInhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitCancer Discov20144445246524444711
   PubMed Web of Science ®Google Scholar
• ChenZChengKWaltonZA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature2012483739161361722425996
   PubMed Web of Science ®Google Scholar
• LuoJEmanueleMJLiDA genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogeneCell2009137583584819490893
   PubMed Web of Science ®Google Scholar
• WeisbergENonamiAChenZIdentification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignanciesLeukemia Epub552014
   Google Scholar
• HaarbergHEParaisoKHWoodEInhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanomaMol Cancer Ther201312690191223538902
   PubMed Web of Science ®Google Scholar
• OlivierMHollsteinMHainautPTP53 mutations in human cancers: origins, consequences, and clinical useCold Spring Harb Perspect Biol201021a00100820182602
   PubMed Web of Science ®Google Scholar
• RothJANguyenDLawrenceDDRetrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancerNat Med1996299859918782455
   PubMed Web of Science ®Google Scholar
• LaneDPCheokCFLainSp53-based cancer therapyCold Spring Harb Perspect Biol201029a00122220463003
   PubMed Web of Science ®Google Scholar
• BykovVJIssaevaNShilovARestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNat Med20028328228811875500
   PubMed Web of Science ®Google Scholar
• BykovVJZacheNStridhHPRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosisOncogene200524213484349115735745
   PubMed Web of Science ®Google Scholar
• SupiotSZhaoHWimanKHillRPBristowRGPRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-statusRadiother Oncol200886340741118237796
   PubMed Web of Science ®Google Scholar
• MagriniRRussoDOttaggioLFronzaGIngaAMenichiniPPRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cellsJ Cell Biochem200810462363237318442053
   PubMed Web of Science ®Google Scholar
• IzettiPHautefeuilleAAbujamraALPRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell linesInvest New Drugs201432578379424838627
   PubMed Web of Science ®Google Scholar
• MayordomoJILoftusDJSakamotoHTherapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccinesJ Exp Med19961834135713658666894
   PubMed Web of Science ®Google Scholar
• LeffersNLambeckAJGoodenMJImmunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trialInt J Cancer200912592104211319621448
   PubMed Web of Science ®Google Scholar
• SpeetjensFMKuppenPJWeltersMJInduction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancerClin Cancer Res20091531086109519188184
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• HiraiHIwasawaYOkadaMSmall-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsMol Cancer Ther20098112992300019887545
   PubMed Web of Science ®Google Scholar
• RajeshkumarNVDe OliveiraEOttenhofNMK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsClin Cancer Res20111792799280621389100
   PubMed Web of Science ®Google Scholar
• ShackelfordDBShawRJThe LKB1-AMPK pathway: metabolism and growth control in tumour suppressionNat Rev Cancer20099856357519629071
   PubMed Web of Science ®Google Scholar
• AvizienyteELoukolaARothSLKB1 somatic mutations in sporadic tumorsAm J Pathol1999154367768110079245
   PubMed Web of Science ®Google Scholar
• JiHRamseyMRHayesDNLKB1 modulates lung cancer differentiation and metastasisNature2007448715580781017676035
   PubMed Web of Science ®Google Scholar
• Sanchez-CespedesMParrellaPEstellerMInactivation of LKB1/STK11 is a common event in adenocarcinomas of the lungCancer Res200262133659366212097271
   PubMed Web of Science ®Google Scholar
• GillRKYangSHMeerzamanDFrequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancerOncogene201130353784379121532627
   PubMed Web of Science ®Google Scholar
• CarreteroJShimamuraTRikovaKIntegrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsCancer Cell201017654755920541700
   PubMed Web of Science ®Google Scholar
• IngeLJFrielJMRicherALLKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stressCancer Lett2014352218719525011082
   PubMed Web of Science ®Google Scholar
• ShackelfordDBAbtEGerkenLLKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenforminCancer Cell201323214315823352126
   PubMed Web of Science ®Google Scholar
• LiuYMarksKCowleyGSMetabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancerCancer Discov20133887087923715154
   PubMed Web of Science ®Google Scholar
• BungardDFuerthBJZengPYSignaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylationScience201032959961201120520647423
   PubMed Web of Science ®Google Scholar
• ShawRJKosmatkaMBardeesyNThe tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stressProc Natl Acad Sci U S A2004101103329333514985505
   PubMed Web of Science ®Google Scholar
• ShawRJLamiaKAVasquezDThe kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metforminScience200531057541642164616308421
   PubMed Web of Science ®Google Scholar
• HolderfieldMDeukerMMMcCormickFMcMahonMTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNat Rev Cancer201414745546724957944
   PubMed Web of Science ®Google Scholar
• RobinsonSDO’ShaughnessyJACoweyCLKonduriKBRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenibLung Cancer201485232633024888229
   PubMed Web of Science ®Google Scholar
• FengYThiagarajanPSMaPCMET signaling: novel targeted inhibition and its clinical development in lung cancerJ Thorac Oncol20127245946722237263
   PubMed Web of Science ®Google Scholar
• SadiqAASalgiaRMET as a possible target for non-small-cell lung cancerJ Clin Oncol20133181089109623401458
   PubMed Web of Science ®Google Scholar
• BurrellRASwantonCTumour heterogeneity and the evolution of polyclonal drug resistanceMol Oncol2014861095111125087573
   PubMed Web of Science ®Google Scholar
• cbioportal.org [homepage on the Internet]cBioPortal for Cancer Genomics Available from: http://www.cbioportal.org/Accessed January 27, 2015
   Google Scholar